🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 23 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 09/04/2010 | 40,01 | 40,01 | 39,22 | 39,68 | -0,33% | 1,97% | 1.525.000 |
| 08/04/2010 | 40,43 | 40,50 | 39,42 | 39,81 | -1,68% | 2,67% | 2.224.600 |
| 07/04/2010 | 40,31 | 41,45 | 40,12 | 40,49 | +0,05% | 3,30% | 2.799.900 |
| 06/04/2010 | 40,51 | 40,66 | 40,06 | 40,47 | -0,44% | 1,48% | 2.434.600 |
| 05/04/2010 | 40,86 | 41,05 | 40,53 | 40,65 | -0,49% | 1,27% | 1.439.200 |
| 01/04/2010 | 41,08 | 41,62 | 40,60 | 40,85 | -0,05% | 2,48% | 1.778.600 |
| 31/03/2010 | 40,89 | 41,67 | 40,83 | 40,87 | +0,02% | 2,05% | 1.904.900 |
| 30/03/2010 | 41,25 | 41,39 | 40,71 | 40,86 | -0,73% | 1,65% | 1.535.400 |
| 29/03/2010 | 41,73 | 41,94 | 40,97 | 41,16 | -1,08% | 2,32% | 1.369.300 |
| 26/03/2010 | 41,78 | 42,12 | 41,29 | 41,61 | +0,14% | 1,99% | 1.210.000 |
| 25/03/2010 | 42,04 | 42,12 | 41,54 | 41,55 | -0,38% | 1,38% | 1.207.800 |
| 24/03/2010 | 42,16 | 42,38 | 41,58 | 41,71 | -1,11% | 1,90% | 1.413.200 |
| 23/03/2010 | 42,33 | 42,46 | 42,02 | 42,18 | -0,71% | 1,04% | 1.087.100 |
| 22/03/2010 | 42,61 | 42,95 | 42,33 | 42,48 | -0,56% | 1,46% | 1.139.900 |
| 19/03/2010 | 42,10 | 42,72 | 41,91 | 42,72 | +2,45% | 1,92% | 3.983.700 |
| 18/03/2010 | 42,36 | 42,68 | 41,58 | 41,70 | -1,65% | 2,60% | 2.066.500 |
| 17/03/2010 | 43,64 | 43,91 | 42,39 | 42,40 | -3,00% | 3,48% | 2.101.700 |
| 16/03/2010 | 43,32 | 43,94 | 43,23 | 43,71 | +1,09% | 1,64% | 1.513.500 |
| 15/03/2010 | 43,39 | 43,73 | 42,75 | 43,24 | -0,51% | 2,26% | 1.428.600 |
| 12/03/2010 | 43,04 | 43,46 | 42,52 | 43,46 | +1,07% | 2,18% | 1.188.500 |
| 11/03/2010 | 42,89 | 43,11 | 42,40 | 43,00 | -0,05% | 1,66% | 1.037.900 |
| 10/03/2010 | 42,22 | 43,14 | 42,11 | 43,02 | +2,23% | 2,44% | 3.012.000 |
| 09/03/2010 | 41,18 | 42,19 | 41,17 | 42,08 | +1,64% | 2,48% | 1.635.900 |
| 08/03/2010 | 41,33 | 41,55 | 41,26 | 41,40 | -0,29% | 0,70% | 687.800 |
| 05/03/2010 | 41,62 | 41,86 | 41,39 | 41,52 | -0,19% | 1,13% | 940.200 |
| 04/03/2010 | 42,00 | 42,08 | 41,25 | 41,60 | -0,91% | 1,98% | 875.600 |
| 03/03/2010 | 41,79 | 42,11 | 41,71 | 41,98 | +0,33% | 0,96% | 1.367.000 |
| 02/03/2010 | 41,83 | 42,03 | 41,27 | 41,84 | +0,99% | 1,82% | 1.105.100 |
| 01/03/2010 | 40,66 | 41,78 | 40,61 | 41,43 | +2,20% | 2,88% | 1.164.300 |
| 26/02/2010 | 40,18 | 40,62 | 39,51 | 40,54 | +1,00% | 2,76% | 1.355.700 |